Stoboclo (DENOSUMAB-BMWO)
Stoboclo (DENOSUMAB-BMWO) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Stoboclo; Generic name: DENOSUMAB-BMWO; Drug class: RANK Ligand Inhibitor [EPC].
| Brand name | Stoboclo |
|---|---|
| Generic name | DENOSUMAB-BMWO |
| Drug class | RANK Ligand Inhibitor [EPC] |
| Manufacturer | CELLTRION USA, Inc. |
| Used for | 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is |
| Dosage | 2 DOSAGE AND ADMINISTRATION Pregnancy must be ruled out prior to administration of Stoboclo. ( 2.1 ) Before initiating Stoboclo in patients with advanced chronic kidney disease, including dialysis patients, evaluate for the presence of chronic kidney disease mineral and bone disorder with intact parathyroid hormone, serum calcium, 25(OH) vitamin D, and 1,25(OH) 2 vitamin D. ( 2.2 , 5.1 , 8.6 ) Stoboclo should be administered by a healthcare provider. ( 2.3 ) Administer 60 mg every 6 months as a |
| Warnings | WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedl |
| Active ingredient(s) | DENOSUMAB |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10b9eea3-bf70-4ff3-a0b9-54248cbfd156 |